Welcome to our dedicated page for Omni Bridgeway news (Ticker: IMMFF), a resource for investors and traders seeking the latest updates and insights on Omni Bridgeway stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Omni Bridgeway's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Omni Bridgeway's position in the market.
Omni Bridgeway (IMMFF) released its Investment Portfolio Report as at 31 December 2025, citing strong completions and fund-raising momentum. Key metrics: A$223.7 million cash investment proceeds in 1H26, A$37.8 million OBL-only proceeds, overall MOIC on completions 2.6x and 3.0x for 2Q26.
Operating expenses are tracking materially below the FY26 budget of A$80 million while fee-only revenues track at the increased A$35 million FY26 target. Funds 4/5 Series II secured US$228 million additional external commitments.